Efrat Makov Sells 5,000 Shares of CRNT
Efrat Makov sold 5,000 shares of CRNT on June 12, 2026, for $14,950.
Key Points
- Efrat Makov sold 5,000 shares of CRNT on June 12, 2026, at $2.99 each, totaling $14,950.
- CRNT shares are trading around $2.99 with notable activity from institutional investors and analysts.
- Needham reiterated a buy rating for CRNT with a $3.00 price target on May 20, 2026.
On June 12, 2026, Efrat Makov sold 5,000 shares of CRNT at $2.99 each, totaling $14,950. This transaction was not part of a pre-planned 10b5-1 trading plan.
Other Institutional Activity in CRNT
Several institutional investors have recently adjusted their positions in CRNT. First Wilshire Securities Management Inc. increased its holdings by 740,358 shares, bringing its total to 4,854,150 shares valued at approximately $10.48 million. In contrast, CSM Advisors, LLC reduced its position by 11,650 shares, ending with 2,272,398 shares worth about $4.91 million. Private Advisor Group, LLC also trimmed its stake by 10,000 shares, leaving it with 1,410,888 shares valued at $3.05 million. WealthTrust Axiom LLC added 43,836 shares, resulting in a total of 944,135 shares, valued at $2.04 million. Meanwhile, KLCM Advisors, Inc. maintained its position at 795,500 shares, worth $1.72 million.
CRNT Stock Snapshot
Shares of CRNT are currently trading around $2.99. The stock has seen varied institutional interest and analyst coverage, which may influence its performance in the coming months.
Insider Buying and Selling at CRNT
Besides Efrat Makov's sale, there was other insider activity at CRNT. On the same day, Makov also bought 5,000 shares at $1.99 each. Doron Ovadia Arazi, CRNT's CEO, purchased 66,667 shares on June 11, 2026, and an additional 133,333 shares on the same day. Rami Hadar bought 29,500 shares on May 23, 2026.
Analysts Set New Price Targets
Needham reiterated its buy rating for CRNT on May 20, 2026, with a price target of $3.00. Lake Street initiated coverage with a buy rating and a $3.50 target on March 31, 2026. The consensus among analysts is generally positive, with a mean price target of $3.00.
Bottom Line
Efrat Makov's recent sale of CRNT shares is part of ongoing insider activity that investors may find noteworthy. While insider transactions can provide insights, they are just one piece of the puzzle. Investors often track these moves, along with institutional activity and analyst ratings, to gauge market sentiment. Remember, 13F filings and insider reports are backward-looking and may not reflect the current state of holdings.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.